Partner David L. Rosen was quoted in a May 10, 2013 Law360 article titled, “Drug Cos. See Path to Legal Off-Label Marketing.” The piece discusses the drug industry’s efforts to push the FDA to support “truthful off-label marketing,” which has the potential to significantly boost the sale of pharmaceuticals. Rosen was quoted as saying, “The sale of products for uses that go beyond the scope of the approved labeled indications is huge. … Companies have paid significant fines for seeking government reimbursement for products sold for off-label uses.” Rosen believes that drug makers are extremely interested in additional information on what the FDA expects of them when it comes to off-label marketing. “We start seeing a little bit of activity by FDA in enforcement, and everybody jumps to a lot of conclusions,” Rosen said. “But those enforcement actions are extremely fact-specific. We’re not well-served if we base our decisions on what to do in these areas on one isolated piece of FDA enforcement.”
People
Related News
27 August 2024
In the News
Samuel Goldstick Assesses Data Privacy Challenges for Automakers
Foley & Lardner LLP partner Samuel Goldstick underscored how disclosure can help automakers reduce legal risk in the Automotive Dive article, "Automakers face growing data privacy challenges, experts say."
26 August 2024
In the News
Judith Waltz Quoted on Inflation Reduction Act, Pharma Impact
Foley & Lardner LLP partner Judith Waltz is quoted in the PharmaVoice article, "Pharmas’ IRA court losses mount. They keep pursuing them."
20 August 2024
In the News
Kevin Hyde Featured in Q&A on Jacksonville Legal Market – 'The outlook is good'
Foley & Lardner LLP partner Kevin Hyde is featured in a Capital Analytics Associates Q&A on the major achievements of Foley's Jacksonville office, key trends in the legal market, and the firm's commitment to its talent and client service.